Consolidation nivolumab/ipilimumab versus nivolumab following concurrent chemoradiation in patients with unresectable stage III NSCLC: A planned interim safety analysis from the BTCRC LUN 16-081 trial.
Melissa Yan(Indiana University Health), Nasser H. Hanna(Ontario Institute for Cancer Research), Hirva Mamdani(Wayne State University), Vinicius Ernani(Emory University), Mary J. Fidler, Naomi Fujioka(University of Minnesota), Jarushka Naidoo(Sidney Kimmel Comprehensive Cancer Center), Borys Hrinczenko(Michigan State University), Salma K. Jabbour(Rutgers, The State University of New Jersey), Greg Andrew Durm(Indiana University Health), Ticiana Leal(University of Wisconsin Carbone Cancer Center), Lawrence Feldman(University of Illinois Chicago), Goetz Kloecker(University of Louisville)
Cited by 12
Related Papers
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
|New England Journal of Medicine|2018|2.1k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Genome-wide cell-free DNA fragmentation in patients with cancer
|Nature|2019|1.5k
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
|Journal of the National Comprehensive Cancer Network|2021|1k